Characterization of filovirus host factors and small-molecule inhibitors of infection
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 473350
Grant search
Key facts
Disease
EbolaStart & end year
2022Known Financial Commitments (USD)
$574,965.45Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Côté MarcelineResearch Location
CanadaLead Research Institution
University of OttawaResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnosticsResearch Subcategory
Pathogen morphology, shedding & natural historySpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
Filoviruses are negative strand RNA viruses that can cause severe hemorrhagic fevers in human following zoonotic spillover events. Outbreaks of filovirus diseases are increasing in frequency and our knowledge of the Filoviridae family expended greatly recently with the discovery of new filoviruses in Europe, Africa and Asia that are also potentially pathogenic. While a vaccine against Ebola virus, one of the 5 species of ebolaviruses, is available, it does not protect well against all ebolaviruses and does not protect against other pathogenic filoviruses. Therefore, pan-filoviral antiviral therapy is urgently needed. In this proposed project, we aim to gain a molecular understanding of the filovirus-host cell interactions with the overarching goal of identifying and characterizing pan-filovirus small molecule inhibitors for the development of new pan-filoviral antiviral therapies.